BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Karolinska Development AB: Pergamum Announces That the First Patient has Been Dosed With Potential New Treatment for Hard-to-Heal Wounds


9/11/2012 10:17:34 AM

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of LL-37 for the treatment of patients with hard-to-heal venous leg ulcers. Karolinska Development AB (STO: KDEV) is the majority owner of Pergamum. "Non-healing wounds are a huge burden for the individual patient and for the health care system. Today, there are an estimated 15 million patients globally, and virtually no medical progress has been made over the last few decades", said Jonas Ekblom, CEO of Pergamum AB. "This clinical trial will allow us to evaluate a promising new treatment, based on the body’s own immune defense, for patients with venous leg ulcers. The ultimate goal is to accomplish faster healing and improved quality of life for patients who typically have a poor prognosis."

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->